Zukavild-M Forte Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Zukavild-M Forte is prescribed as an adjunct to diet and exercise to improve glycemic parameters, including fasting and postprandial blood glucose levels and HbA1c. It is particularly useful for patients inadequately controlled on monotherapy with either agent. The medication should be used with caution in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, headache, and hypoglycemia, especially when combined with other antidiabetic drugs. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure safety and efficacy.